4ami
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | [[ | + | ==Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist bucindolol== |
+ | <StructureSection load='4ami' size='340' side='right' caption='[[4ami]], [[Resolution|resolution]] 3.20Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[4ami]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Meleagris_gallopavo Meleagris gallopavo]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4AMI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4AMI FirstGlance]. <br> | ||
+ | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2CV:HEGA-10'>2CV</scene>, <scene name='pdbligand=G90:2-[(2S)-3-[[1-(1H-INDOL-3-YL)-2-METHYL-PROPAN-2-YL]AMINO]-2-OXIDANYL-PROPOXY]BENZENECARBONITRILE'>G90</scene><br> | ||
+ | <tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1dep|1dep]], [[2vt4|2vt4]], [[2y00|2y00]], [[2y01|2y01]], [[2y02|2y02]], [[2y03|2y03]], [[2y04|2y04]], [[2ycw|2ycw]], [[2ycx|2ycx]], [[2ycy|2ycy]], [[2ycz|2ycz]], [[4amj|4amj]]</td></tr> | ||
+ | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ami FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ami OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ami RCSB], [http://www.ebi.ac.uk/pdbsum/4ami PDBsum]</span></td></tr> | ||
+ | <table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The beta(1)-adrenoceptor (beta(1)AR) is the site of action of beta blockers used in the treatment of cardiac-related illnesses. Two beta blockers, carvedilol and bucindolol, show distinctive activities compared to other beta blockers and have been proposed as treatments tailored to the Arg/Gly389(8.56) polymorphism of the human beta(1)AR. Both carvedilol and bucindolol are classified as biased agonists, because they stimulate G protein-independent signaling, while acting as either inverse or partial agonists of the G protein pathway. We have determined the crystal structures of a thermostabilized avian beta(1)AR mutant bound to bucindolol and to carvedilol at 3.2 and 2.3 A resolution, respectively. In comparison to other beta blockers, bucindolol and carvedilol interact with additional residues, in extracellular loop 2 and transmembrane helix 7, which may promote G protein-independent signaling. The structures also suggest that there may be a structural explanation for the pharmacological differences arising from the Arg/Gly389(8.56) polymorphism. | ||
- | + | Crystal Structures of a Stabilized beta(1)-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol.,Warne T, Edwards PC, Leslie AG, Tate CG Structure. 2012 May 9;20(5):841-9. PMID:22579251<ref>PMID:22579251</ref> | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
+ | </div> | ||
- | + | ==See Also== | |
- | + | *[[Adrenergic receptor|Adrenergic receptor]] | |
- | + | == References == | |
- | + | <references/> | |
- | + | __TOC__ | |
- | + | </StructureSection> | |
- | + | ||
- | == | + | |
- | [[ | + | |
- | + | ||
- | == | + | |
- | < | + | |
[[Category: Meleagris gallopavo]] | [[Category: Meleagris gallopavo]] | ||
[[Category: Edwards, P C.]] | [[Category: Edwards, P C.]] |
Revision as of 08:34, 5 June 2014
Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist bucindolol
|